Get startedLog in
    Picture of China Medical System Holdings logo

    867 — China Medical System Holdings News Story

    0.000.00%
    hk flag iconLast trade - 00:00
    HealthcareAdventurousMid CapNeutral
    All News

    Brief: CMS Says NDA For Additional Indication Atopic Dermatitis For Ruxolitinib Phosphate Cream Accepted

    Picture of China Medical System Holdings logoChina Medical System Holdings
    24/02/2026 13:54
    Feb 24 (Reuters) - China Medical System Holdings Ltd 0867.HK:

CMS (867.HK/8A8.SG): NDA FOR ADDITIONAL INDICATION ATOPIC DERMATITIS (AD) FOR RUXOLITINIB PHOSPHATE CREAM ACCEPTED AND GRANTED PRIORITY REVIEW IN CHINA

CHINA MEDICAL SYSTEM HOLDINGS - REVIEW TIMELINE SHORTENED FROM 200 DAYS TO 130 DAYS

Source text: ID:nGNX93bPCr

Further company coverage: 0867.HK

 (((( Reuters.briefs@thomsonreuters.com ;));))

    Recent news on China Medical System Holdings

    See all news